Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy

Experimental and Therapeutic Medicine

Volumn 11, Issue 5, 2016, Pages 1601-1610

  Jia, Hejin ^a   Tian, Yaping ^b   Jiang, Chao Guang ^c   Han, Weidong ^a  

^a Biotherapeutic Department   (China)

^b State Key Laboratory of Kidney Disease   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Albumin; Chemotherapy; Cytokine induced killer; Non small cell lung cancer; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; CYTOKINE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CYTOKINE INDUCED KILLER CELL; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; NON SMALL CELL LUNG CANCER; PHENOTYPE; PROGRESSION FREE SURVIVAL;

EID: 84961842662     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3102     Document Type: Article

References (52)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. She J, Yang P, Hong Q and Bai C: Lung cancer in China: Challenges and interventions. Chest 143: 1117-1126, 2013.
3. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc 83: 584-594, 2008.
4. Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, Vansteenkiste JF and Pirker R: Lung cancer: Progress in diagnosis, staging and therapy. Respirology 15: 44-50, 2010.
5. Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J and Gridelli C: Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 45: 2473-2487, 2009.
6. Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12: 298-306, 2012.
7. Fischbach MA, Bluestone JA and Lim WA: Cell-based therapeutics: The next pillar of medicine. Sci Transl Med 5: 179ps7, 2013.
8. Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2: 363-368, 2011.
9. Lu PH and Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696, 1994.
10. Jiang J, Wu C and Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med 11: 83, 2013.
11. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY and Chen JM: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8: 464-468, 2002.
12. Yang L, Ren B, Li H, Yu J, Cao S, Hao X and Ren X: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62: 65-73, 2013.
13. Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S, et al: Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 19: 4347-4358, 2013.
14. Jakel CE, Vogt A, Gonzalez-Carmona MA and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res 2014: 897214, 2014.
15. Zhang Y, Wang J, Wang Y, Lu XC, Fan H, Liu Y, Zhang Y, Feng KC, Zhang WY, Chen MX, et al: Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clin Dev Immunol 2013: 195691, 2013.
16. Kim JS, Chung IS, Lim SH, Park Y, Park MJ, Kim JY, Kim YG, Hong JT, Kim Y and Han SB: Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma. Arch Pharm Res 37: 559-566, 2014.
17. Wu C, Jiang J, Shi L and Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28: 3997-4002, 2008.
18. Shi SB, Ma TH, Li CH and Tang XY: Effect of maintenance therapy with dendritic cells: Cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98: 314-319, 2012.
19. Han RX, Liu X, Pan P, Jia YJ and Yu JC: Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One 9: e108958, 2014.
20. Chen Y, Lin G, Guo ZQ, Zhou ZF, He ZY and Ye YB: Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PloS One 8: e69044, 2013.
21. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567, 2014.
22. González-Cao M: Immunotherapy for lung cancer. Transl Lung Cancer Res 4: 675-677, 2015.
23. Mahoney KM and Atkins MB: Prognostic and predictive markers for the new immunotherapies. Oncology 28 Suppl 3: 39-48, 2014.
24. Wang Y, Dai H, Li H, Lv H, Wang T, Fu X and Han W: Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol 2011: 621414, 2011.
25. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Näslund TI and Gabrielsson S: Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res 73: 3865-3876, 2013.
26. Belardelli F and Ferrantini M: Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23: 201-208, 2002.
27. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49, 2011.
28. Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H and Jin CB: Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 30: 1217-1222, 2004.
29. Ciernik IF, Berzofsky JA and Carbone DP: Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 156: 2369-2375, 1996.
30. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P and Ferrone S: Immunotherapy of cancer in 2012. CA Cancer J Clin 62: 309-335, 2012.
31. Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X and Li H: Autologous cytokine-induced killer cell immunotherapy in lung cancer: A phase II clinical study. Cancer Immunol Immunother 61: 2125-2133, 2012.
32. Li DP, Li W, Feng J, Chen K and Tao M: Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer. Oncol Res 22: 67-74, 2015.
33. Zhong R, Han B and Zhong H: A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 35: 987-994, 2014.
34. Zhong R, Teng J, Han B and Zhong H: Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60: 1497-1502, 2011.
35. Li Y, Huang SL, Wu YF, Wei J, Bao R and Zhou DH: Expansion of CIK/NK cells from cord blood by using different combinations of stem cell factor, FLT3 ligand and interleukin 2, 7, 15 in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12: 350-354, 2004 (In Chinese).
36. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, Huang K and Zhou DH: Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 30: 3493-3499, 2010.
37. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB and Craig WY: Reference distributions for the negative acute-phase serum protein–s, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 13: 273-279, 1999.
38. Don BR and Kaysen G: Serum albumin: Relationship to inflammation and nutrition. Semin Dial 17: 432-437, 2004.
39. von Meyenfeldt M: Cancer-associated malnutrition: An introduction. Eur J Oncol Nurs 9 (Suppl 2): S35-S38, 2005.
40. Gupta D and Lis CG: Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J 9: 69, 2010.
41. Yeun JY and Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 32 (Suppl 4): S118-S125, 1998.
42. Siddiqui A, Heinzerling J, Livingston EH and Huerta S: Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg 194: 362-366, 2007.
43. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincón D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E and Mohar-Betancourt A: Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14: 381-389, 2007.
44. Lis CG, Grutsch JF, Vashi PG and Lammersfeld CA: Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr 27: 10-15, 2003.
45. Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, Negrier S, Dumontet C and Mackey JR: Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 107: 2698-2705, 2006.
46. Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM and Huang RP: Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845: 182-201, 2014.
47. Souza SL, Montalli Da Assumpção LV and Ward LS: Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 13: 491-495, 2003.
48. Krauze MT, Tarhini A, Gogas H and Kirkwood JM: Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol 33: 385-391, 2011.
49. Weber J: Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58: 823-830, 2009.
50. Braumuller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature 494: 361-365, 2013.
51. Salih HR, Rammensee HG and Steinle A: Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002.
52. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J and Fox BA: The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 11: 54, 2013.